{"id":"NCT01728077","sponsor":"UCB Pharma SA","briefTitle":"Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy","officialTitle":"An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy Phase 3b","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-10","primaryCompletion":"2016-08","completion":"2016-08","firstPosted":"2012-11-16","resultsPosted":"2017-08-02","lastUpdate":"2018-07-11"},"enrollment":26,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Brivaracetam","otherNames":["UCB34714"]}],"arms":[{"label":"Brivaracetam","type":"EXPERIMENTAL"}],"summary":"N01372 study is to evaluate the long-term safety, tolerability, maintenance of efficacy of Brivaracetam (BRV); as well as the effect of BRV on subjects' health-related quality of life and to explore the direct medical resource use for BRV (for subjects entering N01372 from a study where pharmacoeconomic data was collected). BRV will be used at doses up to maximum of 200 mg/day, as adjunctive treatment in subjects aged 16 years or older with Epilepsy.","primaryOutcome":{"measure":"Incidence of Treatment Emergent Adverse Events (TEAEs) During Evaluation Period","timeFrame":"From Entry Visit (Month 0) to the Last Evaluation Period Visit or Early Discontinuation Visit (up to 46 months)","effectByArm":[{"arm":"Brivaracetam Focal Epilepsy (SS)","deltaMin":78.9,"sd":null},{"arm":"Brivaracetam Generalized Epilepsy (SS)","deltaMin":71.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":7},"locations":{"siteCount":10,"countries":["United States","France","Germany","Spain"]},"refs":{"pmids":["26899665"],"seeAlso":["https://www.briviact.com/briviact-PI.pdf?v=1479491757","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":19},"commonTop":["Headache","Urinary tract infection","Back pain","Nausea","Fatigue"]}}